Shan Bin-Bin, Li Yuan, Zhao Chang, An Xiao-Qin, Zhang Quan-Mao
Department of Pneumology, Shanxi Tumor Hospital, Taiyuan 030000, Shanxi Province, China.
Endoscopy Center, Shanxi Tumor Hospital, Taiyuan 030000, Shanxi Province, China.
World J Clin Cases. 2022 Feb 26;10(6):1883-1888. doi: 10.12998/wjcc.v10.i6.1883.
Insertions in exon 19 in the epidermal growth factor receptor gene (EGFR) is a rarely seen mutation in non-small cell lung cancer. These patients have been effectively treated with sequential EGFR tyrosine kinase inhibitors (TKIs).
Here, we presented a case of non-small cell lung cancer, stage IIIB, with exon 19 insertion mutation as detected in the right lower lobe by next-generation sequencing. The patient was sequentially treated with first, second, and third-generation EGFR TKIs after the surgical operation. The overall survival of the patient was 21.3 mo. There was no dynamic analysis of drug resistance mechanisms in targeted therapy.
This case emphasized the importance of following the guidelines. In patients with mutations, repeated and dynamic next-generation sequencing monitoring is necessary to prescribe a personalized treatment plan.
表皮生长因子受体基因（EGFR）外显子19插入是一种在非小细胞肺癌中罕见的突变。这些患者已通过序贯性表皮生长因子受体酪氨酸激酶抑制剂（TKIs）得到有效治疗。
在此，我们报告1例ⅢB期非小细胞肺癌病例，通过二代测序发现右下叶存在外显子19插入突变。该患者术后依次接受了第一代、第二代和第三代表皮生长因子受体酪氨酸激酶抑制剂治疗。患者的总生存期为21.3个月。靶向治疗中未进行耐药机制的动态分析。
本病例强调了遵循指南的重要性。对于存在突变的患者，重复且动态的二代测序监测对于制定个性化治疗方案是必要的。
